Single center, open and single arm clinical study on the safety and efficacy of r2-mtx-epoch regimen in the treatment of CD5 positive diffuse large B cell lymphoma

Start Date01 Feb 2021

Sponsor / Collaborator

Affiliated Hospital of Xuzhou Medical University

CTRI/2020/10/028220 / RecruitingPhase 2IIT

A phase II randomized study to evaluate the efficacy of short-course RR CVEP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma.

Start Date05 Oct 2020

Sponsor / Collaborator-

NCT03214627 / TerminatedNot Applicable

ANEMEX UK Trial: Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial

Fresenius Medical Care has developed a computer software programme called the Anaemia Control Management (ACM) software to assist in the anaemia management of patients with chronic kidney disease (CKD) undergoing hemodialysis. This trial is designed to assess the effectiveness of this ACM software on anaemia management in routine clinical practice. However, all ultimate decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the discretion of the Investigator. The trial consists of a retrospective (historical) control period and a prospective (going forward) period. During the prospective period, the ACM will be used to assist the Investigators' decision making and will help the Investigators to administer a personalised intravenous (IV) iron and red blood cell stimulating agent (ESA) therapy, whereas treatment according to standard of care will be documented retrospectively for the same patients during the retrospective period of the trial. Thus, patients can serve as their own control.

Start Date10 Dec 2018

Sponsor / Collaborator

Vifor Fresenius Medical Care Renal Pharma Ltd.

[+2]

100 Clinical Results associated with Epoetin beta

100 Translational Medicine associated with Epoetin beta

100 Patents (Medical) associated with Epoetin beta

596

Literatures (Medical) associated with Epoetin beta

01 Jan 2024·Internal medicine (Tokyo, Japan)

Successful Treatment of Primary Mediastinal Large B-cell Lymphoma with DA-EPOCH-Rituximab Therapy in a Transgender Woman

Article

Author: Komiyama, Tomomi ; Nakaseko, Chiaki ; Sugiura, Yoshiya ; Tanaka, Sho ; Shimizu, Naomi ; Abe, Kazuki ; Nakao, Sanshiro

In recent years, lesbian, gay, bisexual, and transgender (LGBT) populations have been gaining acceptance in society. However, very few cases of malignancy in the LGBT population have been reported thus far. We herein report a transgender woman receiving estrogen supplementation who developed primary mediastinal large B-cell lymphoma (PMBCL) and was treated with dose-adjusted EPOCH-rituximab (DA-EPOCH-R) therapy. The patient achieved complete remission after the sixth course of DA-EPOCH-R therapy. To help this LGBT patient continue receiving chemotherapy smoothly on admission, adjusting the hospital environment, such as the allocation of rooms, was essential.

01 Dec 2023·International journal of surgery case reports

Diffuse large B-cell lymphoma from duodenal with hematemesis, melena, and obstruction jaundice symptoms: A rare case

Author: Vidyani, Amie ; Kusuma, Victor Perdana

INTRODUCTION:

Non-Hodgkin lymphoma of the duodenum with manifestation of hematemesis, melena, and obstructive jaundice is a rare occurrence.

CASE PRESENTATION:

A 47-year-old Indonesian man presented with symptoms of hematemesis of 3×/day, melena, abdominal pain, decreased appetite, and a weight loss (2 kg). The patient had symptoms of weakness, jaundice, pale conjunctiva, and experienced palpable discomfort in the epigastric region (VAS of 6). An abdominal ultrasonography revealed a heterogeneous cystic tumor mass measuring 45 × 29 mm located in the pancreas head. The gastrointestinal endoscopy revealed erosive gastritis and a tumor in the duodenum. The patient received a biliodigestive surgery and biopsy for double bypass. The pathological anatomy findings indicated the presence of non-Hodgkin lymphoma. The immunohistochemical results showed that the tumor cells were positive for CD45, CD20, and Ki67 95 % but negative for CK and CD3. The patient had a series of chemotherapy treatments include RCHOP, ICE, and EPOCH for a duration of 1½ years. Subsequently, the patient was assessed and pronounced to be cured.

DISCUSSION:

The identification of diffuse large B-cell lymphoma (DLBCL) from duodenum in this case was challenging due to the presence of unspecific symptoms such as hematemesis, melena, and obstructive jaundice. Management of DLBCL involved surgical interventions and sequential chemotherapy, which have shown the most significant enhancement in prognosis.

CONCLUSION:

The diagnostic accuracy of DLBCL from duodenal site enhances the effectiveness of the therapy employed, leading to a favorable prognosis.

01 Dec 2023·European journal of haematology

Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia

Article

Author: Oehler, Vivian G ; Zarling, Lucas C ; Cooper, Jason P ; Hendrie, Paul C ; Halpern, Anna B ; Walter, Roland B ; Martino, Christen H ; Cassaday, Ryan D ; Estey, Elihu H ; Orozco, Johnnie J ; Soma, Lorinda A ; Stevenson, Philip A ; Becker, Pamela S ; Percival, Mary-Elizabeth M ; Ghiuzeli, Cristina M

Abstract:

Objectives:

We recently performed a single‐arm phase II trial of DA‐EPOCH in adults with acute lymphoblastic leukemia (ALL). We sought to compare these results to those with standard Hyper‐CVAD.

Methods:

We created a retrospective matched cohort of patients who received Hyper‐CVAD (n = 69) at our center and otherwise met eligibility criteria for the DA‐EPOCH trial (n = 53).

Results:

Our outcomes support the use of Hyper‐CVAD over DA‐EPOCH in Ph− disease for both overall survival (OS; HR 0.18, p = .004) and event‐free survival (EFS; HR 0.51, p = .06). In contrast, outcomes were similar in Ph+ disease (OS HR 0.97, p = .96; EFS HR 0.65, p = .21). Rates of morphologic remission and measurable residual‐disease negativity were similar between the regimens. Hyper‐CVAD was associated with significantly more febrile neutropenia (OR 1.9, p = .03) and a greater incidence of Grade 4 or 5 adverse events (20% vs. 6%). Average transfusions per cycle of both red blood cells (p < .001) and platelets (p < .001) were five‐fold higher with Hyper‐CVAD.

Conclusions:

Our findings support continued use of Hyper‐CVAD for Ph− ALL but suggest that DA‐EPOCH may be a reasonable alternative for Ph+ ALL. These data also highlight a potential role for DA‐EPOCH in resource‐limited settings or when more intense therapy is not feasible.

News (Medical) associated with Epoetin beta

29 Aug 2023

·www.biospace.com

BMS Gets FDA Label Expansion for Potential Mega Blockbuster Reblozyl

Pictured: Bristol Myers Squibb in NJ/iStock, arlutz73 Bristol Myers Squibb is advancing towards its $4 billion-plus sales aspirations for Reblozyl with another indication added to its label. Monday, BMS announced that the FDA bumped up the therapy to a first-line treatment option for anemia in adults with low- to intermediate-risk myelodysplastic syndromes who may require regular blood transfusions. Reblozyl, a recombinant fusion protein designed to suppress the Smad2/3 signaling pathway to increase red blood cell counts, was first authorized in 2019 for anemia in beta-thalassemia. The therapy, co-marketed with Merck, was approved for myelodysplastic syndromes (MDS)-related anemia in 2020 but only in patients who had failed to respond to an erythropoiesis-stimulating agent (ESA), the historically front-line treatment. The label expansion was backed by data from the Phase III COMMANDS study, which put BMS’ therapy head-to-head with the ESA standard of care treatment. Over 58% of patients treated with Reblozyl achieved transfusion independence compared to 31% of patients receiving epoetin alfa, the ESA drug manufactured by Amgen and Johnson & Johnson marketed as Epogen and Procrit, respectively. The trial also proved the drug was effective in patients with and without ring sideroblasts—blood cells with iron deposits circling the nucleus. Previous approval had limited the drug’s use to MDS patients exhibiting this common symptom. “Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia,” according to the company’s press release. BMS has high hopes for the therapy. Second-quarter 2023 sales came in at $234 million. As the company works to add more indications to the drug’s label, BMS is projecting sales of over $4 billion by 2030. Reblozyl is also in a Phase III trial for myelofibrosis patients with myeloproliferative neoplasm slated for a readout in 2025. However, competition may be heating up in the MDS market as Geron Corporation submitted its NDA earlier this month for a first-in-class telomerase inhibitor to treat transfusion-dependent anemia with lower risk MDS. Tested in a Phase III trial against a placebo, imetelstat showed significantly higher results in the eight-week transfusion independence endpoint. “The majority of patients with MDS experience chronic anemia and require RBC transfusions,” Tracey Iraca, executive director of the MDS Foundation, said in the BMS press release. “The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients.” Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.

Phase 3Clinical ResultDrug ApprovalNDA

02 Jun 2023

·www.biospace.com

Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer

New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of choice for biopharma companies as evidenced in over a dozen investigational studies across multiple therapeutic approaches SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical significance of minimal residual disease (MRD) assessment at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6 in Chicago, as well as the European Hematology Association (EHA) Hybrid Congress taking place June 8-11 in Frankfurt, Germany. Data will be presented from clinical trials and real-world evidence studies using Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay for MRD assessment across a range of hematologic cancers. “The clinical trial and real-world evidence that is being presented this year at ASCO and EHA showcase clonoSEQ’s utility as the gold standard in MRD assessment both to inform clinical decision making and help assess deep responses to novel therapeutics in patients with hematologic cancers,” said Nitin Sood, chief commercial officer, MRD, at Adaptive Biotechnologies. “Adaptive has demonstrated the value of NGS-MRD assessment in hematologic cancers. The use of MRD assessment in clinical trials and practice continues to mount, and we are pleased to see new data generated that attest to its benefit for physicians, patients and researchers alike.” MRD can be used to assess depth of response and detect early signs of relapse prior to clinical symptoms. This assessment is performed as a series of tests in clinical trials and throughout a patient’s cancer journey. The clonoSEQ Assay is the first and only NGS-MRD test authorized by the U.S. Food and Drug Administration (FDA) for MRD assessment in certain hematologic malignancies. The assay is also offered as a CLIA-validated laboratory developed test for assessing MRD in diffuse large B-cell lymphoma (DLBCL). The clinical findings presented at both ASCO and EHA highlight the prognostic value and clinical actionability of precise, sensitive MRD assessment in hematologic cancers utilizing the clonoSEQ Assay. In various stages of multiple myeloma (MM), real-world evidence and clinical trial results reinforce the clinical significance of sustained MRD negativity and depth of response in the prediction of patient outcomes, including overall survival and progression free survival (PFS). In adults with acute lymphoid leukemia (ALL), real-world evidence found a higher rate of residual disease detection by clonoSEQ as compared to detection with flow cytometry. This data underscores the highly accurate, sensitive and standardized properties of clonoSEQ as compared to other technologies used to assess disease burden. Data continues to show the potential for MRD assessment to help in the personalization of cancer care. For example, interim data in older patients with DLBCL demonstrated that the use of MRD assessment from ctDNA with clonoSEQ in combination with imaging has potential to inform treatment decisions to shorten the duration of therapy. Final analysis from the multi-center Phase 2 MASTER trial showed that in newly diagnosed MM patients treated with quadruplet therapy and monitored using clonoSEQ, the three-year PFS was higher in patients with sustained MRD negativity compared to those who did not achieve MRD negativity. Furthermore, 73% of patients that discontinued therapy based on their MRD status remained free of therapy with sustained MRD negativity. The MASTER trial has been key for studying the feasibility of an MRD-informed approach to treatment discontinuation. The final outcomes reinforce that patients who achieve MRD negativity over time, as measured by clonoSEQ, may be able to discontinue treatment to find relief from treatment side effects and enable substantial savings for the health care system. Presentations will also highlight the value of utilizing NGS-MRD testing in clinical trials to assess the effectiveness of investigational, novel therapeutics. Key ASCO 2023 Presentations Presentation Type and Number Title Presentation Timing Multiple Myeloma Oral Abstract 8001 Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with a safety run-in Saturday, June 3 1:15-4:15 p.m. CDT Poster Abstract 8028 Measurable residual disease (MRD) and clonal diversity for multiple myeloma treatment monitoring Monday, June 5 8:00-11:00 a.m. CDT Poster Abstract 8029 Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study Monday, June 5 8:00-11:00 a.m. CDT Poster Abstract 8031 Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM) Monday, June 5 8:00-11:00 a.m. CDT Poster Abstract TPS8066 MagnetisMM-7: An open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma Monday, June 5 8:00-11:00 a.m. CDT Poster Abstract 8009 CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma Monday, June 5 3:00-4:30 p.m. CDT Acute Lymphoblastic/Lymphoid Leukemia Oral Abstract 7007 A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL) Friday, June 2 1:00-4:00 p.m. CDT Poster Abstract 7033 Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study Monday, June 5 8:00-11:00 a.m. CDT Non-Hodgkin’s Lymphoma Poster Abstract 7554 Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL) Monday, June 5 8:00-11:00 a.m. CDT Key EHA 2023 Presentations Presentation Type and Number Title Presentation Timing Multiple Myeloma Poster Abstract P931 Isatuximab in relapsed multiple myeloma patients with ultra-high-risk cytogenetics: ICARIA-MM and IKEMA subgroup analysis Friday, June 9 6:00 p.m.-7 p.m. CEST Poster Abstract P871 Idecabtagene vicleucel (ide-cel) in patients with an inadequate response to frontline autologous stem cell transplantation (ASCT): results from KARMMA-2 cohort 2C Friday, June 9 6:00 p.m.-7:00 p.m. CEST Oral Abstract S203 Quadruplet induction therapy, ASCT and MRD-modulated consolidation and treatment cessation in newly diagnosed multiple myeloma: final analysis of the MASTER trial Saturday, June 10 2:45 p.m.-4:15 p.m. CEST Chronic Lymphocytic Leukemia Poster Abstract P620 Genetic alterations and outcomes with fixed-duration ibrutinib+venetoclax (Ibr+Ven): results from the Phase 3 GLOW study in patients with previously untreated CLL Friday, June 9 6:00 p.m.-7:00 p.m. CEST About the clonoSEQ Assay The clonoSEQ Assay is the first and only FDA-cleared in vitro diagnostic (IVD) test service to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ testing for diffuse large B-cell lymphoma (DLBCL) patients is currently available for clinical use as a laboratory-developed test (LDT) performed at Adaptive's CLIA-certified lab in Seattle, WA. Medicare covers clonoSEQ in these four indications and is aligned with clinical practice guidelines which support assessing MRD at multiple time points throughout therapy to monitor treatment response and help predict patient outcomes. The clonoSEQ Assay leverages Adaptive Biotechnologies’ proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The assay provides standardized, accurate, and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to therapy over time, monitor patients during remission, and predict potential relapse. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ Assay in patients diagnosed with CLL, MM, ALL and DLBCL. For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit About Adaptive Biotechnologies Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. Forward Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including any statements regarding our market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. ADAPTIVE MEDIA Erica Jones, Associate Director, Corporate Communications 206-279-2423 media@adaptivebiotech.com ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations 201-396-1687 investors@adaptivebiotech.com

Phase 2Phase 3Clinical ResultASCO

23 Jan 2023

·www.prnewswire.com

$12.8 Billion Worldwide Erythropoietin Drugs Industry to 2027 - Featuring Amgen, Biocon, Dr. Reddy's Laboratories and Intas Pharmaceuticals Among Others

DUBLIN, Jan. 21, 2023 /PRNewswire/ -- Research and Markets The "Erythropoietin Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global erythropoietin drugs market size reached US$ 9.8 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 13.8 Billion by 2027, exhibiting a CAGR of 5.87% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor. Erythropoietin (EPO) is a hormone produced by kidneys to stimulate the production of red blood cells (RBCs). Its deficiency can lead to low hemoglobin levels and various medical conditions. As a result, there is a rise in the demand for EPO drugs, also known as EPO stimulating agents (ESAs), which are produced synthetically using recombinant deoxyribonucleic acid (DNA) technology. They are usually administered via the intramuscular route and released into the bloodstream to stimulate RBC production. At present, they are available in various types with different dosage schedules and modes of delivery. EPO drugs are generally given to patients undergoing chemotherapy, chronic renal failure, and antiviral drug therapy or at high risk for perioperative blood loss from surgical procedures. Individuals who have anemia due to cancer, prematurity, and chronic kidney disease (CKD) are usually at the risk of low hemoglobin levels. This represents one of the key factors positively influencing the sales of EPO drugs worldwide. In addition, they are used to treat zidovudine among patients with human immunodeficiency virus (HIV) infection. Moreover, the rising need for surgical interventions on account of the growing aging population across the globe is catalyzing the use of EOP drugs to minimize allogeneic blood transfusions after surgical procedures. Furthermore, the escalating demand for minimally invasive (MI) procedures is bolstering the growth of the market. Apart from this, the increasing use of EPO drugs as a novel therapeutic agent in research settings is projected to expand their applications in treating various diseases. These diseases generally include spinal cord injury (SCI), depression, diabetes, acute kidney injury (AKI), recombinant therapy for patients with heart failure, and a neuroprotective agent in ischemic stroke. Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report: How has the global erythropoietin drugs market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global erythropoietin drugs market? What are the key regional markets? What is the breakup of the market based on the drug class? What is the breakup of the market based on the product type? What is the breakup of the market based on the application? What is the breakup of the market based on the end user? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global erythropoietin drugs market and who are the key players? What is the degree of competition in the industry? Key Topics Covered: 1 Preface 2 Scope and Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Erythropoietin Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Drug Class 6.1 Biologics 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Biosimilars 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Product Type 7.1 Epoetin-alfa 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Epoetin-beta 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Darbepoetin-alfa 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Application 8.1 Hematology 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Kidney Disorder 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Cancer 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Others 8.4.1 Market Trends 8.4.2 Market Forecast 9 Market Breakup by End User 9.1 Hospitals 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Homecare 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Specialty Clinics 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Others 9.4.1 Market Trends 9.4.2 Market Forecast 10 Market Breakup by Region 11 SWOT Analysis 12 Value Chain Analysis 13 Porters Five Forces Analysis 14 Price Analysis 15 Competitive Landscape 15.1 Market Structure 15.2 Key Players 15.3 Profiles of Key Players 15.3.1 Amgen Inc. 15.3.1.1 Company Overview 15.3.1.2 Product Portfolio 15.3.1.3 Financials 15.3.1.4 SWOT Analysis 15.3.2 Biocon Limited 15.3.2.1 Company Overview 15.3.2.2 Product Portfolio 15.3.2.3 Financials 15.3.2.4 SWOT Analysis 15.3.3 Dr. Reddy's Laboratories Ltd. 15.3.3.1 Company Overview 15.3.3.2 Product Portfolio 15.3.3.3 Financials 15.3.3.4 SWOT Analysis 15.3.4 F. Hoffmann-La Roche AG 15.3.4.1 Company Overview 15.3.4.2 Product Portfolio 15.3.4.3 Financials 15.3.5 Intas Pharmaceuticals Ltd. 15.3.5.1 Company Overview 15.3.5.2 Product Portfolio 15.3.6 Johnson & Johnson 15.3.6.1 Company Overview 15.3.6.2 Product Portfolio 15.3.6.3 Financials 15.3.6.4 SWOT Analysis 15.3.7 LG Chem Ltd. 15.3.7.1 Company Overview 15.3.7.2 Product Portfolio 15.3.7.3 Financials 15.3.7.4 SWOT Analysis 15.3.8 Pfizer Inc. 15.3.8.1 Company Overview 15.3.8.2 Product Portfolio 15.3.8.3 Financials 15.3.8.4 SWOT Analysis 15.3.9 Sun Pharmaceutical Industries Limited 15.3.9.1 Company Overview 15.3.9.2 Product Portfolio 15.3.9.3 Financials 15.3.9.4 SWOT Analysis 15.3.10 Teva Pharmaceutical Industries Ltd. 15.3.10.1 Company Overview 15.3.10.2 Product Portfolio 15.3.10.3 Financials 15.3.10.4 SWOT Analysis For more information about this report visit Media Contact: Laura Wood | +353-1-481-1716 | [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

100 Deals associated with Epoetin beta

External Link

KEGG	Wiki	ATC	Drug Bank
D03232	Epoetin beta	B03XA01	DB00016

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Neonatal	JP	Chugai Pharmaceutical Co., Ltd.	20 Apr 2006
Anemia	EU	Roche Registration GmbH	16 Jul 1997
Anemia	IS	Roche Registration GmbH	16 Jul 1997
Anemia	LI	Roche Registration GmbH	16 Jul 1997
Anemia	NO	Roche Registration GmbH	16 Jul 1997
chronic renal failure anemia	EU	Roche Registration GmbH	16 Jul 1997
chronic renal failure anemia	IS	Roche Registration GmbH	16 Jul 1997
chronic renal failure anemia	LI	Roche Registration GmbH	16 Jul 1997
chronic renal failure anemia	NO	Roche Registration GmbH	16 Jul 1997
Anemia of renal disease	JP	Chugai Pharmaceutical Co., Ltd.	23 Jan 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Insufficiency	Phase 3	FR	Roche Pharma AG	01 Oct 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2022	Not Applicable	Myelodysplastic Syndromes First line	338	ESA	ldjefxgpfk(madokbstde) = nqaxvxpfrd fpcqklfyrn (dyunzbzfqx ) View more	-	10 Jun 2022
ASCO2022	Not Applicable	Myelodysplastic Syndromes First line	338	ESA use	eaowodbrty(soovxleciq) = sejaudrmee ehjfvetnjt (rxysjitoib )	Positive	02 Jun 2022
				No ESA use	ozmubkimrh(yhypjpxbdg) = brqizpxtiy avrtcdfvoo (cqhmxqpxny )
ASN2021	Not Applicable	-	260	IV PEG-epoetin beta	turnkbvgim(biqxxsjjuy) = sggkwuqdjc yyzshwuebo (pacwarmccp ) View more	Positive	27 Oct 2021
				sc epoetin beta	turnkbvgim(biqxxsjjuy) = lzdnvcpdia yyzshwuebo (pacwarmccp ) View more
NCT02707757 (CTgov)	Phase 4	Anemia	197	Iron sucrose (Iron Sucrose)	okbkeiqpcx(evrylzdrgb) = xubtgdhlbr esegewahmf (qpytkpauke, gcowggsubq - xhubwyxzmc) View more	-	09 Mar 2021
				Erythopoietin stimulating agent (Neorecormon)	okbkeiqpcx(evrylzdrgb) = dhfztykmed esegewahmf (qpytkpauke, ecgnyuldcp - mnmhkhqyel) View more
NCT02145026 (CTgov)	Phase 4	Myelodysplastic Syndromes	100	Epoetin beta	tgspcvxfot(apcmactgaz) = ciiuzkurlj xacuwbtpyp (bbwkzrxbux, ewsymqwijq - rluvqhlfri) View more	-	24 Apr 2020
NCT01015352 (Pubmed \| Haematologica)	Phase 2	Myelodysplastic Syndromes	98	Azacitidine	iqhutxcllj(tfuoclvccm) = oclcvghkoj gfaupiurvx (objgwfgyek ) View more	-	01 Aug 2016
				Azacitidine + Epoetin-β	iqhutxcllj(tfuoclvccm) = ockhhsrdcj gfaupiurvx (objgwfgyek ) View more
NCT00321919 (CTgov)	Phase 3	chronic renal failure anemia	605	epoetin beta [NeoRecormon] (Early Epoetin Beta Therapy)	pndiradoas(mcosunjkxu) = bqtkbnizgy owjwjjpfbr (oqnvnadwup, jqdbvlwzxg - mdgvetuldt) View more	-	25 May 2016
				epoetin beta [NeoRecormon] (Late Epoetin Beta Therapy)	pndiradoas(mcosunjkxu) = wbgzjtztrh owjwjjpfbr (oqnvnadwup, qfymjnmhau - phhamkvage) View more
NCT00354341 (CTgov)	Phase 3	Anemia \| Diabetic Nephropathies	170	Epoetin beta (Group 1 (Early Epoetin Beta))	exlbfzgmft(kgfyzqemoo) = jypmurulrr bjotckoxhp (nuefhvdvjv, gyuixbityj - xrqgoldgfr) View more	-	31 Mar 2016
				Epoetin beta (Group 2 (No/Late Epoetin Beta))	exlbfzgmft(kgfyzqemoo) = yegollqrvb bjotckoxhp (nuefhvdvjv, bddkphacue - eoowhdubmx) View more
FP670 (ERA2015)	Not Applicable	CD45	84	CERA	tcnbflkabc(ztscgwvpnx) = jqzrnwqmbv raishywoot (lepgijhdbg )	Positive	21 May 2015
				Epoetin-beta	tcnbflkabc(ztscgwvpnx) = skesebvsgh raishywoot (lepgijhdbg )
MP481 (ERA2014)	Not Applicable	Chronic Kidney Diseases N-terminal pro-B-type natriuretic peptide (NT-proBNP)	2,060	C.E.R.A. once-monthly dosing	bagxlnreqw(lxyninohbz) = unjlawvied ozzweeykne (gjxxwnakwo )	Positive	01 May 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis